Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.61 |
| ▸ | GAA | P10253 | 2/20 | 0.61 |
| ▸ | PGR | P06401 | 1/20 | 0.61 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | MMP2 | P08253 | 1/20 | 0.51 |
| ▸ | FABP3 | P05413 | 5/20 | 0.50 |
| ▸ | FABP7 | O15540 | 4/20 | 0.50 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.50 |
| ▸ | BCHE | P06276 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL37865 | 0.83 | ALDH1A1 (0.65) | ALDH1A1HSD17B10GAAPGRPTGS1 | |
| SCHEMBL7181428 | 0.83 | ALDH1A1 (0.65) | ALDH1A1HSD17B10GAAPGRPTGS1 | |
| SCHEMBL29901836 | 0.83 | ALDH1A1 (0.65) | ALDH1A1HSD17B10GAAPGRPTGS1 | |
| SCHEMBL864919 | 0.82 | ALDH1A1 (0.62) | ALDH1A1HSD17B10GAAPGRPTGS1 | |
| SCHEMBL399266 | 0.82 | ALDH1A1 (0.62) | ALDH1A1HSD17B10GAAPGRPTGS1 | |
| SCHEMBL27059849 | 0.81 | ALOX5 (0.70) | ALDH1A1HSD17B10GAAPGRPTGS1 | |
| SCHEMBL9864907 | 0.80 | ALDH1A1 (0.61) | ALDH1A1HSD17B10GAAPGRPTGS1 | |
| SCHEMBL1395198 | 0.80 | ALDH1A1 (0.61) | ALDH1A1HSD17B10GAAPGRPTGS1 | |
| SCHEMBL3362842 | 0.80 | ALDH1A1 (0.61) | ALDH1A1HSD17B10GAAPGRPTGS1 | |
| Alpha-Naphthylacetate SCHEMBL76633 | 0.80 | ALDH1A1 (0.66) | ALDH1A1HSD17B10GAAPGRPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 350 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011032159-A1 | METHODS TO PREVENT A HAIR-RELATED SIDE EFFECT OF TREATMENT WITH A CHEMOTHERAPEUTIC AGENT | META COMESTICS, LLC (US) | 2011-03-17 | — | — | WO | claimed |
| US-20110002866-A1 | METHODS TO PREVENT A HAIR-RELATED SIDE EFFECT OF TREATMENT WITH A CHEMOTHERAPEUTIC AGENT | LUBIT BEVERLY W | 2011-01-06 | — | — | US | claimed |
| US-20050148662-A1 | Dinuclear copper-based and compound and ligand for nucleic acid scission and anticancer treatment | JOHNS HOPKINS UNIVERSITY | 2005-07-07 | — | — | US | claimed |
| US-20050090479-A1 | Dinuclear cooper-based compounds and ligamd for nucleic acid scission and anticancer treatment | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-04-28 | — | — | US | claimed |
| US-20050026897-A1 | Trinuclear copper-based compound and ligand for nucleic acid scission and anticancer treatment | UNIVERSITY OF MARYLAND | 2005-02-03 | — | — | US | claimed |
| US-6670363-B1 | 2-(2,4-Difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol -1-yl) propyl)-4-(4-(4-(4-chlorophenyl)-1-piperazinyl)phenyl) -3-(2H,4H)-1,2,4-triazolone; opportunistic fungal infections | RANBAXY LABORATORIES LIMITED (IN) | 2003-12-30 | — | — | US | claimed |
| WO-2003054145-A2 | DINUCLEAR COPPER-BASED COMPOUND AND LIGAND FOR NUCLEIC ACID SCISSION AND ANTICANCER TREATMENT | UNIVERSITY OF MARYLAND, COLLEGE PARK (US) | 2003-07-03 | — | — | WO | claimed |
| WO-2003052058-A2 | DINUCLEAR COPPER-BASED COMPOUND AND LIGAND FOR NUCLEIC ACID SCISSION AND ANTICANCER TREATMENT | UNIVERSITY OF MARYLAND, COLLEGE PARK (US) | 2003-06-26 | — | — | WO | claimed |
| EP-0889881-B1 | NEW TRIAZOLES AS THERAPEUTIC AGENTS FOR FUNGAL INFECTIONS | NAEJA PHARMACEUTICAL INC (CA) | 2003-04-23 | — | — | EP | claimed |
| EP-1278755-A2 | AZOLE COMPOUNDS AS THERAPEUTIC AGENTS FOR FUNGAL INFECTIONS | Ranbaxy Laboratories, Limited (IN) | 2003-01-29 | — | — | EP | claimed |
| WO-2002095050-A2 | TRINUCLEAR COPPER-BASED COMPOUND AND LIGAND FOR NUCLEIC ACID SCISSION AND ANTICANCER TREATMENT | UNIVERSITY OF MARYLAND, COLLEGE PARK (US) | 2002-11-28 | — | — | WO | claimed |
| WO-2001066551-A2 | AZOLE COMPOUNDS AS THERAPEUTIC AGENTS FOR FUNGAL INFECTIONS | RANBAXY LABORATORIES LIMITED (IN) | 2001-09-13 | — | — | WO | claimed |
| US-6153616-A | Triazoles as therapeutic agents for fungal infections | SYNPHAR LABORATORIES, INC. (CA) | 2000-11-28 | — | — | US | claimed |
| EP-0889881-A1 | NEW TRIAZOLES AS THERAPEUTIC AGENTS FOR FUNGAL INFECTIONS | SYNPHAR LABORATORIES INC. (CA) | 1999-01-13 | — | — | EP | claimed |
| WO-1998031675-A1 | NEW TRIAZOLES AS THERAPEUTIC AGENTS FOR FUNGAL INFECTIONS | SYNPHAR LABORATORIES, INC. (US) | 1998-07-23 | — | — | WO | claimed |
| US-5401766-A | Hypotensive agents with vasodilation | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-03-28 | — | — | US | claimed |
| US-5158959-A | Treatment of hypertension | HOECHST AKTIENGESELLSCHAFT (DE) | 1992-10-27 | — | — | US | claimed |
| US-4292238-A | Alkylation of benzthiazole-azo-phenylamine dyestuffs | BAYER AKTIENGESELLSCHAFT (DE) | 1981-09-29 | — | — | US | claimed |
| WO-2024128000-A1 | ISOPOLYOXOTUNGSTATE SALT COMPOUND, SOLVATE THEREOF OR MIXTURE OF SAID COMPOUND AND SOLVATE, AND METHOD FOR PRODUCING SAID COMPOUND, SOLVATE OR MIXTURE | 東京応化工業株式会社 | 2024-06-20 | — | — | WO | disclosed |
| US-3993609-A | ACID SENSITIVE AZO PROMOTERS | PENNWALT CORPORATION (US) | 1976-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110002866-A1 | METHODS TO PREVENT A HAIR-RELATED SIDE EFFECT OF TREATMENT WITH A CHEMOTHERAPEUTIC AGENT | PGF, PTGS1, PTGS2 | ALDH1A1 498/4885HSD17B10 380/4885GAA 4194/4885 |
| US-20050148662-A1 | Dinuclear copper-based and compound and ligand for nucleic acid scission and anticancer treatment | DDB1, POLN, DNASE1 | ALDH1A1 438/4885HSD17B10 1732/4885GAA 1017/4885 |
| US-20050090479-A1 | Dinuclear cooper-based compounds and ligamd for nucleic acid scission and anticancer treatment | LIG1, LIG4, LIG3 | ALDH1A1 1667/4885HSD17B10 2479/4885GAA 1872/4885 |
| US-20050026897-A1 | Trinuclear copper-based compound and ligand for nucleic acid scission and anticancer treatment | DDX21, DDB1, RNASE1 | ALDH1A1 1305/4885HSD17B10 2762/4885GAA 689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.